Understanding Healthcare Professionals’ Perspectives on Cannabis for Medical Purposes in Canada: A Scoping Review
- 1Canadian Centre on Substance Use and Addiction, Ottawa, ON, Canada
- 2Independent Researcher, Cagliari, Italy
- 3King’s University College at Western University, London, ON, Canada
Abstract
Background: The legalization of recreational cannabis in Canada has raised significant challenges for healthcare providers (HCPs), who are increasingly requested to navigate conversations with patients about cannabis use, effects, benefits, and risks.
Summary: This scoping review aimed to: (1) identify HCP knowledge gaps and barriers related to medical cannabis use; (2) explore their perceptions and practices surrounding medical cannabis use in healthcare; and (3) assess HCP education and training needs. A search of PubMed, PsycNet, CINAHL, and grey literature identified 240 studies published between October 2018 and March 2026 that focused on Canadian HCP views, practices, challenges and needs related to medical cannabis. Of 187 articles screened, 26 met inclusion criteria. HCP-endorsed uses for medical cannabis were primarily for treatment of oncological nausea pain, chronic pain, and pediatric epilepsy. Many HCPs remain hesitant to consider cannabis in their treatment plans due to limited knowledge and training, stigma, regulatory challenges, cost, and insufficient clinical evidence. Across studies, HCPs expressed a strong desire for more formal cannabis education and clearer regulatory and institutional guidance.
Key Messages: HCPs in Canada remain cautious about integrating cannabis into clinical care, citing safety concerns, limited clinical evidence, and systemic barriers. Addressing these challenges through targeted education and clearer clinical guidance may help build HCP confidence and support safer, evidence-informed patient care.
Related
- Understanding Cervical Screening Engagement Among Young South Asian Women: Perspectives of Women and Healthcare Professionals
- Accessibility of essential medicines and vaccines among fisherfolk, artisanal miners and pastoralists in Mainland Tanzania: a qualitative study of barriers and strategies from the perspectives of healthcare professionals and community leaders.
- Healthcare Professionals' Perspectives toward Innovation in Palliative Care across European Settings: An Exploratory Mixed-Methods Study
- Healthcare professionals' perspectives on diagnostic delay in rare cancers and options for patient support: a qualitative interview study.
- What is an ideal mHealth for post-discharge home care of CHD: perspectives from primary caregivers, healthcare professionals, and project technical consultants: a qualitative research study
BibTeX
@article{renard2026understanding,
title = {{Understanding Healthcare Professionals’ Perspectives on Cannabis for Medical Purposes in Canada: A Scoping Review}},
author = {Justine Renard and Marta De Felice and Katarina Kane and Laura G. Rosen},
journal = {Medical Cannabis and Cannabinoids},
year = {2026},
month = jul,
doi = {10.1159/mca/adoag001},
url = {https://doi.org/10.1159/mca/adoag001},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Understanding Healthcare Professionals’ Perspectives on Cannabis for Medical Purposes in Canada: A Scoping Review
AU - Justine Renard
AU - Marta De Felice
AU - Katarina Kane
AU - Laura G. Rosen
PY - 2026
DA - 2026/07/23
JO - Medical Cannabis and Cannabinoids
DO - 10.1159/mca/adoag001
UR - https://doi.org/10.1159/mca/adoag001
AB - Background: The legalization of recreational cannabis in Canada has raised significant challenges for healthcare providers (HCPs), who are increasingly requested to navigate conversations with patients about cannabis use, effects, benefits, and risks. Summary: This scoping review aimed to: (1) identify HCP knowledge gaps and barriers related to medical cannabis use; (2) explore their perceptions and practices surrounding medical cannabis use in healthcare; and (3) assess HCP education and training needs. A search of PubMed, PsycNet, CINAHL, and grey literature identified 240 studies published between October 2018 and March 2026 that focused on Canadian HCP views, practices, challenges and needs related to medical cannabis. Of 187 articles screened, 26 met inclusion criteria. HCP-endorsed uses for medical cannabis were primarily for treatment of oncological nausea pain, chronic pain, and pediatric epilepsy. Many HCPs remain hesitant to consider cannabis in their treatment plans due to limited knowledge and training, stigma, regulatory challenges, cost, and insufficient clinical evidence. Across studies, HCPs expressed a strong desire for more formal cannabis education and clearer regulatory and institutional guidance. Key Messages: HCPs in Canada remain cautious about integrating cannabis into clinical care, citing safety concerns, limited clinical evidence, and systemic barriers. Addressing these challenges through targeted education and clearer clinical guidance may help build HCP confidence and support safer, evidence-informed patient care.
SN - 2504-3889
ER -